Inactive Instrument

Medisun Precision Medicine Ltd.

MPME

MHY595141026

Advanced Medical Equipment & Technology

Accurexa Seeks Financing

March 25, 2015 at 12:00 am

Accurexa Inc. (OTCBB:ACXA) needs additional capital to become profitable and competitive, and execute strategic acquisitions and it may have to raise additional capital.

Latest news about Medisun Precision Medicine Ltd.

Medisun Precision Medicine Ltd. acquired New Sonic Global Limited from Sun Medical Operation Company Limited for $3.8 million.	17-07-24	CI
Accurexa, Inc. Enters into a License Agreement with Medisun Holdings Limited to Use Medisun's NK Cell Technology	17-06-09	CI
Accurexa, Inc. Announces Management Changes	17-04-20	CI
Accurexa, Inc. Appoints Stefan Moll as Chief Financial Officer	17-03-02	CI
Accurexa Inc. Enters into Sublicense Agreement with CNMRGS Inc	17-02-07	CI
Accurexa, Inc. Announces Management Changes	17-01-19	CI
Accurexa Partners with Stemimmune to Develop Stem Cell-Mediated Immunotherapy for Cancer Patients	16-10-18	CI
DelMar Pharmaceuticals and Accurexa to Collaborate in the Development of a Novel Combination Chemotherapy for the Local Treatment of Brain Cancer	16-09-07	CI
Medisun Precision Medicine Ltd. Auditor Raises 'Going Concern' Doubt	15-08-05	CI
Accurexa Inc. Announces Directorate Changes	15-07-02	CI
Medisun Precision Medicine Ltd. announced that it has received $2.25 million in funding	15-06-21	CI
Accurexa Inc. announced that it expects to receive $2.25 million in funding.	15-06-15	CI
Accurexa Seeks Financing	15-03-25	CI
Accurexa, Inc. Enters into an Exclusive License Agreement with the Regents of the University of California	14-09-17	CI
Cyto Wave Technologies Inc. will Change its Name to Accurexa Inc	14-08-21	CI
Cyto Wave Technologies Inc. will Change its Ticker to ACXA from CWAV	14-08-21	CI
Cyto Wave Technologies Inc. Appoints Luc H. Meyer as Director	13-09-10	CI
Cyto Wave Technologies Inc. announced that it has received $0.97 million in funding	12-11-28	CI
Cyto Wave Technologies Inc. announced that it expects to receive $1 million in funding.	12-09-14	CI

Chart Medisun Precision Medicine Ltd.

Duration

Period

More charts

Medisun Precision Medicine Ltd. is a development-stage company. The Company is focused on developing neurological therapies to be directly delivered into specific regions of the brain. The Company is developing its ACX-31 program to deliver approximately two chemotherapy drugs, temozolomide in combination with biodegradable 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) locally to brain tumor sites. Through its second development program, it is developing BranchPoint device that can deliver therapeutics through the radial deployment of a delivery catheter to large and anatomically complex brain targets through a single initial brain penetration. It is based on a neurosurgical delivery platform, which can enable approaches to neurological therapy and be modified for the delivery of a range of therapeutics, such as stem cells to treat neurodegenerative diseases, chemotherapeutics to brain tumors and gene therapy vectors.

Sector

Advanced Medical Equipment & Technology

More about the company

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
THERMO FISHER SCIENTIFIC	+12.15%	227B
DANAHER CORPORATION	+14.90%	197B
INTUITIVE SURGICAL, INC.	+18.22%	141B
BOSTON SCIENTIFIC CORPORATION	+29.15%	110B
SIEMENS HEALTHINEERS AG	+0.53%	64.15B
EDWARDS LIFESCIENCES CORPORATION	+16.92%	53.72B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+6.33%	51.75B
AGILENT TECHNOLOGIES, INC.	+10.93%	45.2B
GE HEALTHCARE TECHNOLOGIES INC.	+5.87%	37.37B

Other Advanced Medical Equipment & Technology

Medisun Precision Medicine Ltd.

Equities

MPME

MHY595141026

Advanced Medical Equipment & Technology

Accurexa Seeks Financing

Latest news about Medisun Precision Medicine Ltd.

Chart Medisun Precision Medicine Ltd.

Company Profile

Sector Other Advanced Medical Equipment & Technology